

### **PION Antibody**

Catalog # ASC11271

### **Specification**

# **PION Antibody - Product Information**

Application
Primary Accession
Other Accession
Reactivity
Host
Clonality
Isotype
Application Notes

WB, IHC-P, IF, E
A4D1B5
NP\_059135, 54103
Human, Mouse, Rat
Rabbit
Polyclonal
IgG
PION antibody can be used for detection of

Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.

PION by Western blot at 0.25 μg/mL.

# **PION Antibody - Additional Information**

Gene ID **54103** 

#### **Target/Specificity**

PION antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human PION.<br/>
<br/>
The immunogen is located within amino acids 770 - 820 of PION.

### **Reconstitution & Storage**

PION antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

### **Precautions**

PION Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

# **PION Antibody - Protein Information**

Name GSAP

**Synonyms PION** 

#### **Function**

Regulator of gamma-secretase activity, which specifically activates the production of amyloid-beta protein (amyloid-beta protein 40 and amyloid-beta protein 42), without affecting the cleavage of other gamma-secretase targets such has Notch. The gamma-secretase complex is an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). Specifically promotes the gamma- cleavage of APP CTF-alpha (also named APP-CTF) by the gamma-secretase complex to generate amyloid-beta, while it reduces the epsilon-cleavage of APP CTF-alpha, leading to a low production of AICD.



**Cellular Location**Golgi apparatus, trans-Golgi network


**Tissue Location** Widely expressed...

# **PION Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

### **PION Antibody - Images**




Western blot analysis of IRF3 in (A) human kidney and (B) rat kidney lysate with IRF3 antibody at  $1 \mu g/mL$ ..

# **PION Antibody - Background**

PION Antibody: Accumulation of the amyloid-beta peptide (Abeta) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. The beta-amyloid protein precursor (APP) is cleaved by one of two beta-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99 -amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for gamma-secretase to generate the 4 kDa amyloid-beta peptide (Abeta), which is deposited in the Alzheimer's disease patient's brains. PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both gamma-secretase and the APP C-terminal fragment, suggesting that PION may be a potential therapeutic target for the treatment of Alzheimer's disease.

# **PION Antibody - References**





Tel: 858.875.1900 Fax: 858.875.1999

Ponte P, Gonzalez-DeWhitt P, Schilling J, et al. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature1988; 331:525-77.

Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol.1994; 10:373-403.

He G, Luo W, Li P, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's diease. Nature2010; 467:95-9.